

# Michał, Szczyrek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3003806/publications.pdf>

Version: 2024-02-01

28  
papers

287  
citations

840776

11  
h-index

996975

15  
g-index

28  
all docs

28  
docs citations

28  
times ranked

418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review. <i>Nutrients</i> , 2021, 13, 2217.	4.1	42
2	Biomarkers of alcohol misuse: recent advances and future prospects. <i>Przegląd Gastroenterologiczny</i> , 2016, 2, 78-89.	0.7	30
3	Chronic obstructive pulmonary disease in farmers and agricultural workers - an overview. <i>Annals of Agricultural and Environmental Medicine</i> , 2011, 18, 310-3.	1.0	22
4	Promoter polymorphisms of <i>TOP2A</i> and <i>ERCC1</i> genes as predictive factors for chemotherapy in non-small cell lung cancer patients. <i>Cancer Medicine</i> , 2020, 9, 605-614.	2.8	20
5	Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. <i>Annals of Hematology</i> , 2020, 99, 2881-2891.	1.8	18
6	Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2020, 191, 77-89.	2.5	16
7	MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5193-5200.	1.8	14
8	lvabradine attenuates the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. <i>Epilepsy Research</i> , 2017, 133, 67-70.	1.6	13
9	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review. <i>Cancers</i> , 2020, 12, 2314.	3.7	13
10	Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients. <i>Frontiers in Oncology</i> , 2020, 10, 563613.	2.8	12
11	Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1109.	2.4	11
12	The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings. <i>Archives of Medical Science</i> , 2016, 6, 1263-1272.	0.9	8
13	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?. <i>PLoS ONE</i> , 2021, 16, e0257484.	2.5	8
14	Polymorphisms in the promotor region of the <i>CRBN</i> gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. <i>British Journal of Haematology</i> , 2019, 186, 695-705.	2.5	7
15	Methylation of DROSHA and DICER as a Biomarker for the Detection of Lung Cancer. <i>Cancers</i> , 2021, 13, 6139.	3.7	7
16	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. <i>Oncology Reports</i> , 2013, 30, 1463-1472.	2.6	6
17	Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 607-614.	1.9	6
18	Polymorphisms in the promoter region of the <i>CRBN</i> gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 24054-24068.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. <i>Cancers</i> , 2021, 13, 4806.	3.7	5
20	New prognostic biomarkers in multiple myeloma. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 811-819.	0.1	5
21	Effect of <i>TOP2A</i> and <i>ERCC1</i> gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients. <i>Archives of Medical Science</i> , 2021, 17, 474-480.	0.9	4
22	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. <i>Cells</i> , 2022, 11, 752.	4.1	4
23	Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer. <i>Cells</i> , 2022, 11, 956.	4.1	4
24	Acute urticaria: an extremely rare adverse effect of levonorgestrel-releasing intrauterine system as a possible manifestation of progesterone hypersensitivity syndrome. <i>Postepy Dermatologii I Alergologii</i> , 2018, 35, 530-531.	0.9	2
25	Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1126.	2.4	2
26	The efficacy of T790M mutation testing in liquid biopsy – Real clinic data. <i>PLoS ONE</i> , 2022, 17, e0267846.	2.5	2
27	Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review. <i>Annals of Agricultural and Environmental Medicine</i> , 2021, 29, 103-109.	1.0	0
28	The impact of intestinal microflora on the effectiveness of immunotherapy with antibodies against immune checkpoints – case report and literature review. <i>Oncology in Clinical Practice</i> , 2018, 14, 226-231.	0.1	0